Citations

Showing 10 of 108083 citations.

Prevalence of skin cancer in Native American kidney transplant recipients
Ilyas, Muneeb , Ginsberg, Zachary , Temkit, M’hamed , Keddis, Mira T. , Keddis, Mira, Ginsberg, Zachary , Sharma, Amit

Mayo Clinic

International Journal of Dermatology | December 19, 2017 | Volume: 57 | Issue: 4 | Pages: 406-409

10.1111/ijd.13863 | PMID 29265357 Get It

AbstractBackgroundSkin cancer prevalence is well‐characterized for white solid organ transplant recipients. Although the prevalence of skin cancer in non‐white (Black, Asian, Hispanic) kidney transplant recipients (KTRs) has been assessed, no study has reported the prevalence of skin cancer in Native American (NA) KTRs. The aim of this study is to determine if the prevalence of skin cancer in NAKTRs is the same as in white KTRs.MethodsWe conducted a case‐controlled retrospective review from a single transplant center. One hundred thirteen NAKTRs who received a transplant between 2001 and 2011 were age‐ and transplant‐year matched with 113 white controls.ResultsThe 226 KTRs consisted of 141 (62.4%) men and 85 (37.6%) women, with a mean age of 50.2 ± 10.8 years. There was no skin cancer found in NAKTRs prior to or post transplantation, while seven (6.2%) white KTRs had eight skin cancers prior to transplantation, and 28 (24.8%) white KTRs developed 66 skin cancers post transplantation. Twenty‐two (19.5%) NAKTRs did not follow‐up with dermatology at this institution. The median follow‐up in NAKTRs was 3.3 years compared to 3.0 years in white KTRs.ConclusionNAKTRs have a decreased prevalence of skin cancer compared to their white counterparts.
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis
Tefferi, Ayalew , Shah, Sahrish, Mudireddy, Mythri , Barraco, Daniela , Hanson, Curtis A. , Elliott, Michelle A. , Patnaik, Mrinal S., Pardanani, Animesh , Gangat, Naseema , Lasho, Terra L. , Barraco, Daniela , Gangat, Naseema , Ketterling, Rhett P. , Patnaik, Mrinal S.

Mayo Clinic

British Journal of Haematology | December 19, 2017 | Volume: 183 | Issue: 5 | Pages: 835-838

10.1111/bjh.15061 | PMID 29265333 Get It

Revision Multiligament Knee Reconstruction: Clinical Outcomes and Proposed Treatment Algorithm
O’Malley, Michael, Krych, Aaron J. , Reardon, Patrick J., Johnson, Nick R., Levy, Bruce A. , Woodmass, Jarret M, O'Malley, Michael P, Krych, Aaron J , Woodmass, Jarret Murray , Stuart, Michael J.

Mayo Clinic

Arthroscopy | December 19, 2017 | Volume: 34 | Issue: 3 | Pages: 736

10.1016/j.arthro.2017.09.022 | PMID 29273255 Get It

Purpose To (1) assess clinical outcomes of revision multiligament knee injury (MLKI) reconstruction at a minimum of 2 years' follow‐up and (2) present a standardized treatment algorithm used in treating revision MLKI patients. Methods A retrospective review of our institution's MLKI database was performed to identify all patients who underwent revision MLKI reconstructions (≥2 ligaments reconstructed) after implementation of a standardized treatment algorithm in 2000 and had a minimum of 2 years' follow‐up. Patient demographic information, injury description (mechanism of injury, neurovascular status, knee dislocation grade, associated chondral or meniscal injury), surgical technique (repair vs reconstruction, staged vs nonstaged, concomitant procedures), mechanism of failure, knee stability, and range of motion, as well as International Knee Documentation Committee and Lysholm scores, were obtained. Results We assessed 23 patients (8 female and 15 male patients), with an average age of 26.7 ± 11.5 years at primary surgery and 30.8 ± 11.0 years at revision surgery. The mean follow‐up period was 7.5 ± 5.3 years. Of the 23 patients, 10 (43.4%) underwent staged revision procedures: isolated bone grafting in 3, osteotomy in 4, hardware removal with osteochondral allograft in 1, hardware removal with bone grafting in 1, and meniscus repair for a locked knee in 1. The average International Knee Documentation Committee and Lysholm scores were 74.5 ± 22.3 and 79.4 ± 20.2, respectively. High‐energy injury and increasing age at revision surgery were the only risk factors found to be associated with significantly worse outcomes ( P < .05). Conclusions Patients with recurrent instability after MLKI reconstruction present with many concomitant pathologies, including limb malalignment, bone tunnel widening, retained hardware, meniscal incompetence, and cartilage defects. Revision MLKI reconstruction can provide these patients with modest functional outcomes when a standardized treatment algorithm is used focusing on identification and treatment of the concomitant pathology, often in a staged manner. Level of Evidence Level IV, case series.
Academic dissertations from the Danish Headache Center 1980–2016
Dodick, David W.

Mayo Clinic

Cephalalgia | December 19, 2017 | Volume: 37 | Issue: 2_suppl | Pages: 3-3

10.1177/0333102417724937 | PMID 29256258 Get It

Tinea capitis mimicking dissecting cellulitis in three children
Shastry, Jennifer , Ciliberto, Heather, Davis, Dawn Marie R. , Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | December 19, 2017 | Volume: 35 | Issue: 1 | Pages: No page available

10.1111/pde.13343 | PMID 29265536 Get It

AbstractTinea capitis mimicking dissecting cellulitis is a rare presentation, and there is a paucity of information regarding this presentation in the literature. Three children 10‐14 years of age who presented with an unusual clinical manifestation of tinea capitis that clinically resembled dissecting cellulitis are reported. The patients were treated with systemic antifungals for 3‐4 months. Treatment success was measured according to repeat fungal cultures and clinical assessment of hair regrowth at follow‐up visits. All three patients had resolution of infection, with negative repeat fungal cultures and complete hair regrowth without scarring. These cases highlight a rare inflammatory subtype of tinea capitis that can be easily misdiagnosed and therefore improperly treated, prolonging the duration of infection.
Clinical Factors That Predict a Second ACL Injury After ACL Reconstruction and Return to Sport: Preliminary Development of a Clinical Decision Algorithm
Paterno, Mark V. , Huang, Bin , Thomas, Staci , Hewett, Timothy E. , Schmitt, Laura C.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | December 19, 2017 | Volume: 5 | Issue: 12 | Pages: No page available

10.1177/2325967117745279 | PMID 29318172 Get It

Background: Biomechanical predictors of a second anterior cruciate ligament (ACL) injury after ACL reconstruction (ACLR) and return to sport (RTS) have been identified; however, these measures may not be feasible in a standard clinical environment. Purpose/Hypothesis: The purpose of this study was to evaluate whether standard clinical measures predicted the risk of second ACL injuries. The hypothesis tested was that a combination of strength, function, and patient-reported measures at the time of RTS would predict the risk of second ACL injuries with high sensitivity and specificity. Study Design: Case-control study; Level of evidence, 3 and Cohort study (prognosis); Level of evidence, 1. Methods: A total of 163 participants (mean age, 16.7 ± 3.0 years) who underwent primary ACLR and were able to RTS were evaluated. All participants completed an assessment of isokinetic strength, hop testing, balance, and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Participants were tracked for a minimum of 24 months to identify occurrences of a second ACL injury. The initial 120 participants enrolled were used to develop a clinical prediction model that utilized classification and regression tree (CART) analysis, and the remaining 43 participants enrolled were used as a validation dataset. Additional analyses were performed in all 163 participants using Kaplan-Meier analysis and Cox proportional hazards modeling. Results: Approximately 20% (23/114) of the initial subset of the cohort suffered a second ACL injury. CART analysis identified age, sex, knee-related confidence, and performance on the triple hop for distance at the time of RTS as the primary predictors of a second ACL injury. Using these variables, a model was generated from which high-risk (n = 53) and low-risk groups (n = 61) were identified. A total of 22 participants in the high-risk group and 1 participant in the low-risk group suffered a second ACL injury. High-risk participants fit 1 of 2 profiles: (1) age <19 years, triple hop for distance between 1.34 and 1.90 times body height, and triple hop for distance limb symmetry index (LSI) <98.5% (n = 43) or (2) age <19 years, triple hop for distance >1.34 times body height, triple hop for distance LSI >98.5%, female sex, and high knee-related confidence (n = 10). The validation step identified the high-risk group as being 5 times (odds ratio, 5.14 [95% CI, 1.00-26.46]) more likely to suffer a second ACL injury, with a sensitivity of 66.7% and specificity of 72.0%. Conclusion: These findings recognize measures that accurately identify young patients at high risk of sustaining a second ACL injury within 24 months after RTS. The development of a clinical decision algorithm to identify high-risk patients, inclusive of clinically feasible variables such as age, sex, confidence, and performance on the triple hop for distance, can serve as a foundation to re-evaluate appropriate discharge criteria for RTS.
Optical coherence tomography in gastroenterology: a review and future outlook
Leggett, Cadman L. , Bergman, Jacques , Tsai, Tsung-Han , Trindade, Arvind J. , Sethi, Amrita, Swager, Anne-Fré, Joshi, Virendra, Bergman, Jacques J., Mashimo, Hiroshi , Nishioka, Norman S., Namati, Eman, Leggett, Cadman L

Mayo Clinic

Journal of Biomedical Optics | December 19, 2017 | Volume: 22 | Issue: 12 | Pages: 1

10.1117/1.jbo.22.12.121716 | PMID 29260538 Get It

Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned
Afzali, Anita , Ciorba, Matthew A. , Sharaf, Mai, Fourment, Chris, Ritter, Timothy E., Wolf, Douglas C. , Shafran, Ira, Randall, Charles , Kane, Sunanda V. , Schwartz, David A. , Fourment, Chris

Mayo Clinic

Inflammatory Bowel Diseases | December 19, 2017 | Volume: 24 | Issue: 1 | Pages: 2-4

10.1093/ibd/izx015 | PMID 29272481 Get It

Abstract Electronic medical records (EMRs) have gained widespread use in clinical practice and by default serve as a large patient database with potential for use in clinical research. Although there remains significant interest in leveraging EMRs for research purposes, extraction of data has proven to be complex and with insufficient accuracy. We describe the limitations of an EMR in our attempt to conduct a seemingly simple study aimed at validating variables identified in the PRECiSE 3, a 7-year open label safety and efficacy study of certolizumab pegol in Crohn’s disease that identified clinical factors that predicted both short- and long-term efficacy. A multicenter, retrospective cohort study from 8 academic and large community practices was performed, and data were collected from each respective EMR. Significant challenges with reliable capture of key data elements were encountered, and overall a screen fail rate of 91.8% across all sites was seen. We describe these challenges and potential future directions to work together to advance accuracy and implementation of the use of EMRs in inflammatory bowel disease.
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer
Molenaar, Remco J. , Sidana, Surbhi , Gerds, Aaron T. , Angelini, Dana E. , Kalaycio, Matt, Nazha, Aziz , Adelstein, David J. , Nasr, Christian , Maciejewski, Jaroslaw P. , Majhail, Navneet S. , Sekeres, Mikkael A. , Radivoyevitch, Tomas, Advani, Anjali S. , Angelini, Dana, Mukherjee, Sudipto, Gerds, Aaron T , Majhail, Navneet S , Sidana, Surbhi , Sekeres, Mikkael A , Radivoyevitch, Tomas , Carraway, Hetty E. , Mukherjee, Sudipto

Mayo Clinic

Journal of Clinical Oncology | December 18, 2017 | Volume: 36 | Issue: 18 | Pages: 1831-1839

10.1200/jco.2017.75.0232 | PMID 29252123 Get It

Purpose To investigate the risk and outcomes of second hematologic malignancies (SHMs) in a population-based cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with radioactive iodine (RAI). Methods Patients with WDTC were identified from SEER registries. Competing risk regression analysis was performed to calculate the risks of SHMs that occurred after WDTC treatment and outcomes after SHM development were assessed. Results Of 148,215 patients with WDTC, 53% received surgery alone and 47% received RAI. In total, 783 patients developed an SHM after a median interval of 6.5 years (interquartile range, 3.3 to 11.2 years) from WDTC diagnosis. In multivariable analysis, compared with those undergoing thyroidectomy alone, RAI treatment was associated with an increased early risk of developing acute myeloid leukemia (AML; hazard ratio, 1.79; 95% CI, 1.13 to 2.82; P = .01) and chronic myeloid leukemia (CML; hazard ratio, 3.44; 95% CI, 1.87 to 6.36; P < .001). This increased risk of AML and CML after RAI treatment was seen even in low-risk and intermediate-risk WDTC tumors. Occurrence of AML but not CML in patients with WDTC was associated with shorter median overall survival compared with matched controls (8.0 years v 31.0 years; P = .001). In addition, AML developing after RAI trended toward inferior survival compared with matched controls with de novo AML (median overall survival, 1.2 years v 2.9 years; P = .06). Conclusion Patients with WDTC treated with RAI had an increased early risk of developing AML and CML but no other hematologic malignancies. AML that arises after RAI treatment has a poor prognosis. RAI use in patients with WDTC should be limited to patients with high-risk disease features, and patients with WDTC treated with adjuvant RAI should be monitored for myeloid malignancies as part of cancer surveillance.
Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia
Saarinen, Alicia M., Hitosugi, Taro , Wang, Liguo , Ho, Thai H. , Liu, Jun , Liu, Jun , Ho, Thai , Wang, Liguo , Zhang, Xiaodong , Wang, Zhenghe

Mayo Clinic

eLife | December 18, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.31132 | PMID 29256392 Get It

Tumor tissues are chronically exposed to hypoxia owing to aberrant vascularity. Lipid droplet (LD) accumulation is a hallmark of hypoxic cancer cells, yet how LDs form and function during hypoxia remains poorly understood. Herein, we report that in various cancer cells upon oxygen deprivation, HIF-1 activation down-modulates LD catabolism mediated by adipose triglyceride lipase (ATGL), the key enzyme for intracellular lipolysis. Proteomics and functional analyses identified hypoxia-inducible gene 2 (HIG2), a HIF-1 target, as a new inhibitor of ATGL. Knockout of HIG2 enhanced LD breakdown and fatty acid (FA) oxidation, leading to increased ROS production and apoptosis in hypoxic cancer cells as well as impaired growth of tumor xenografts. All of these effects were reversed by co-ablation of ATGL. Thus, by inhibiting ATGL, HIG2 acts downstream of HIF-1 to sequester FAs in LDs away from the mitochondrial pathways for oxidation and ROS generation, thereby sustaining cancer cell survival in hypoxia.